Psoriasis: Update Bulletin # 3 [April 2019]

This edition presents the views and insights from three of the world's foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the psoriasis market. Topics covered include opinions regarding Novartis' announcement of additional positive data from the head-to-head CLARITY study, evaluating Cosentyx (secukinumab) against Stelara (ustekinumab; Janssen) in treating adults with moderate to severe plaque psoriasis; insights on UCB's positive Phase IIb BE ABLE 2 extension trial of bimekizumab; as well as AbbVie's announcement that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the IL-23 inhibitor Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis.

Business Questions:

• How do KOLs view the additional head-to-head CLARITY data for Cosentyx versus Stelara?
• What are KOL opinions regarding Novartis' lawsuit against Johnson & Johnson regarding the head-to-head ECLIPSE trial?
• How do experts view bimekizumab's Phase IIb BE ABLE 2 extension study results?
• Do KOLs consider bimekizumab's mechanism of action, blocking both IL-17A and IL-17F cytokines, important?
• What are KOLs' opinions regarding how bimekizumab could potentially be used if approved?
• How clinically attractive is Skyrizi and what are its potential advantages, according to KOLs?
• If approved, where could Skyrizi be positioned in the psoriasis treatment algorithm?